Volixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH). If approved for use, it will be... Volixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane protein primarily expressed by enterocytes of the ileum.
- Mechanism
- Curator reviewed · 1 reference
Volixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane protein primarily expressed by enterocytes of the ileum. ASBT is primarily responsible for the recirculation of bile acids and therefore for hepatic lipid and glucose metabolism. Inhibiting this enzyme results in a decrease of bile acids returning to the liver, which is helpful for the treatment of NASH as abnormal cholesterol metabolism and accumulation of free cholesterol in the liver have been implicated in its pathogenesis.
- Primary indication
- Volixibat is an investigational drug that has not been approved for use in any conditions.Curator reviewed
- Formula / weight
- C38H51N3O12S2 · 805.96 g/mol (avg)
- Code names
- SHP626
Resolves to
ULVBLFBUTQMAGZ-RTNCXNSASA-NSMILES[H][C@@]1([C@@H](O)[C@](CC)(CCCC)CS(=O)(=O)C2=CC=C(C=C12)N(C)C)C1=CC=CC(NC(=O)N[C@@H]2O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](OCC3=CC=CC=C3)[C@H]2O)=C1What you can answer from here — as of September 13, 2026
Which drugs share a target with Volixibat, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account